Tissue-specific induced DNA methyltransferase 1 (Dnmt1) in endocrine pancreas by RCAS-TVA-based somatic gene transfer system promotes β-cell proliferation.
Alpharetrovirus
/ genetics
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Proliferation
/ genetics
Chickens
DNA (Cytosine-5-)-Methyltransferase 1
/ antagonists & inhibitors
Disease Models, Animal
Fibroblasts
Gene Transfer Techniques
Genetic Vectors
/ administration & dosage
Humans
Islets of Langerhans
/ metabolism
Mice
Mice, Transgenic
Molecular Targeted Therapy
/ methods
Multiple Endocrine Neoplasia Type 1
/ drug therapy
Pancreatic Neoplasms
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Up-Regulation
/ drug effects
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
16
04
2018
accepted:
05
08
2018
revised:
31
07
2018
pubmed:
8
9
2018
medline:
3
4
2020
entrez:
8
9
2018
Statut:
ppublish
Résumé
We reported that inactivation of menin (the protein product of MEN1) increases activity of Dnmt1 and mediates DNA hypermethylation in the development of multiple endocrine neoplasia type 1 (MEN1) syndrome. We have developed a RCAS-TVA-based somatic gene transfer system that enables tissue-specific delivery of Dnmt1 to individual β-cells of the pancreas in a RIP-TVA mouse model. In the present study, we mediated Dnmt1 expression in islet β-cells in RIP-TVA mice by utilizing the RCAS-TVA system to test if the upregulation of Dnmt1 can promote β-cell proliferation. In vitro, we demonstrated that upregulation of Dnmt1 increased β-cell proliferation. In vivo, our results showed that the levels of serum insulin were increased in the RIP-TVA mice with RCASBP-Dnmt1 infection compared with wild-type control mice with RCASBP-Dnmt1 infection. Furthermore, we confirmed that mRNA and protein expression of Dnmt1 as well as Dnmt1 enzyme activity were upregulated in the RIP-TVA mice with RCASBP-Dnmt1 infection compared with wild-type control mice with RCASBP-Dnmt1 infection. Finally, we demonstrated that upregulation of Dnmt1 resulted in hyperplasia through β-cell proliferation. We conclude that the upregulation of Dnmt1 promotes islet β-cell proliferation and targeting Dnmt1 may be a promising therapy for patients suffering from pancreatic neuroendocrine tumors.
Identifiants
pubmed: 30190513
doi: 10.1038/s41417-018-0046-x
pii: 10.1038/s41417-018-0046-x
pmc: PMC7540611
mid: NIHMS1634573
doi:
Substances chimiques
Antineoplastic Agents
0
Men1 protein, mouse
0
Proto-Oncogene Proteins
0
DNA (Cytosine-5-)-Methyltransferase 1
EC 2.1.1.37
Dnmt1 protein, mouse
EC 2.1.1.37
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-102Subventions
Organisme : NCI NIH HHS
ID : P50 CA174521
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA170911
Pays : United States
Références
Science. 1997 Apr 18;276(5311):404-7
pubmed: 9103196
PLoS Biol. 2007 Oct 16;5(10):e276
pubmed: 17941720
Oncol Lett. 2015 May;9(5):2307-2312
pubmed: 26137062
Hum Mutat. 2008 Jan;29(1):22-32
pubmed: 17879353
Am J Pathol. 2004 Feb;164(2):689-99
pubmed: 14742272
Subcell Biochem. 2013;61:597-625
pubmed: 23150269
Hum Mutat. 1999;13(3):175-85
pubmed: 10090472
Nature. 2009 Nov 19;462(7271):315-22
pubmed: 19829295
Hum Pathol. 2010 Aug;41(8):1069-78
pubmed: 20381114
Cancer Res. 2009 Mar 1;69(5):1858-66
pubmed: 19208834
Genes Dev. 2002 Jan 1;16(1):6-21
pubmed: 11782440
Ann N Y Acad Sci. 2004 Apr;1014:189-98
pubmed: 15153434
Curr Opin Cell Biol. 2013 Apr;25(2):152-61
pubmed: 23498662
Nat Rev Genet. 2009 Sep;10(9):605-16
pubmed: 19668247
PLoS One. 2011 Jan 14;6(1):e16119
pubmed: 21264250
Oncotarget. 2016 Mar 15;7(11):12633-50
pubmed: 26871472
Science. 2001 Aug 10;293(5532):1068-70
pubmed: 11498573
Eur J Cancer. 2007 Jan;43(2):402-14
pubmed: 17184987
Oncotarget. 2012 Dec;3(12):1546-56
pubmed: 23295859
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Br J Cancer. 2008 Feb 26;98(4):824-31
pubmed: 18268498
Int J Mol Med. 2013 Jul;32(1):59-66
pubmed: 23599173
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
J Clin Invest. 2014 Jan;124(1):17-23
pubmed: 24382385
Cancer Res. 2006 Sep 1;66(17):8397-403
pubmed: 16951149
PLoS One. 2009 Sep 07;4(9):e6932
pubmed: 19812721
Carcinogenesis. 2006 Jun;27(6):1160-8
pubmed: 16537562
EMBO Rep. 2011 Jul 01;12(7):647-56
pubmed: 21660058
PLoS One. 2010 Mar 01;5(3):e9472
pubmed: 20208994
Oncotarget. 2017 Oct 4;8(56):96396-96408
pubmed: 29221215
J Biol Chem. 2007 Oct 26;282(43):31332-40
pubmed: 17766243
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10770-5
pubmed: 12960363
J Intern Med. 1998 Jun;243(6):447-53
pubmed: 9681842
Chin Med J (Engl). 2012 Oct;125(19):3526-31
pubmed: 23044318
Ann Intern Med. 1998 Sep 15;129(6):484-94
pubmed: 9735087
Am J Pathol. 2014 Aug;184(8):2355-64
pubmed: 24911372
Clin Endocrinol (Oxf). 2008 Feb;68(2):271-7
pubmed: 17803708
Hum Mol Genet. 2000 Oct;9(16):2395-402
pubmed: 11005794
Genome Res. 2011 Jul;21(7):1017-27
pubmed: 21521786
Epigenomics. 2014;6(4):415-26
pubmed: 25333850
Cell Rep. 2012 Nov 29;2(5):1411-24
pubmed: 23177624
J Vis Exp. 2017 Oct 16;(128):
pubmed: 29155705
Pathol Oncol Res. 2012 Oct;18(4):1039-45
pubmed: 22777918